+A -A

Tabela:
Comparative View:

3Q19 Create chart
Net sales revenues 1,308,357
Change in Fair Value of Biological Assets 12,129
Cost of Goods Sold -830,288
Depreciation / Amortization / exhaustion -111,621
Exhaustion of biological assets -29,058
Gross Profit 349,519
Selling Expenses -184,497
General and Administrative Expenses -56,169
Management Compensation -4,211
Other Operating Compensation -11,549
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity 93,093
Financial Income 41,096
Financial Expenses -97,828
Income Before Income Tax and Social Contribution 36,361
Income and social contribution taxes - current -21,288
Income Tax and Social Contribution - Deferred 12,642
Effect profit from discontinued operation 0
Net Income 27,715
Recurring Net Income 30,472
Recurring EBITDA 237,913
EBITDA Margin 18.2 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza